Phaseline

Companies › Chong Kun Dang Pharmaceutical

Chong Kun Dang Pharmaceutical: clinical trials, targets and expected readouts

7 active drug programs in 44 registered trials: 17 Phase 4, 12 Phase 2, 10 Phase 1, 5 Phase 3; Oncology, Immunology, Neurology, Cardiovascular; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Mycophenolate Mofetil
Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
IMPDH1, IMPDH2Phase 4Kidney Transplantation; Hypersensitivity Pneumonitis; Liver Transplantation; Lupus Nephritis …Nov 2026
Valsartan
Type-1 angiotensin II receptor antagonist
AGTR1Phase 3Essential Hypertension; Stage D Heart Failure; PreDiabetes; Coronary Artery Disease …Dec 2026
CKD-843–Phase 3Androgenetic AlopeciaSep 2027
CKD-706
IL-4 receptor alpha subunit antagonist monoclonal antibody
–Phase 1Atopic DermatitisNov 2026
CKD-512–Phase 1Advanced Solid TumorsMar 2027
CKD-703
c-Met-targeting monoclonal antibody conjugated to monomethyl auristatin E (MMAE)
METPhase 1Advanced Solid TumorsDec 2029
CKD-704
Risankizumab biosimilar; anti-IL-23 monoclonal antibody
IL23APhase 1Psoriasis–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04191681ValsartanPhase 4Stage D Heart FailureCardiovascularMar 2022
NCT03938389ValsartanPhase 4PreDiabetesMetabolic and endocrineFeb 2024
NCT03938389ValsartanPhase 4PreDiabetesMetabolic and endocrineFeb 2024
NCT03983850Mycophenolate MofetilPhase 1Graft Versus Host DiseaseOncologyNov 2025
NCT05626387Mycophenolate MofetilPhase 4Hypersensitivity PneumonitisImmunologySep 2026
NCT07258745CKD-704Phase 1PsoriasisImmunologySep 2026
NCT05193565Mycophenolate MofetilPhase 4Kidney TransplantationGenitourinaryNov 2026
NCT07358156CKD-706Phase 1Atopic DermatitisImmunologyNov 2026
NCT06917664ValsartanPhase 4Coronary Artery DiseaseCardiovascularDec 2026
NCT05785065Mycophenolate MofetilPhase 2Systemic Sclerosis With Lung InvolvementImmunologyDec 2026
NCT06643819ValsartanPhase 3Essential HypertensionCardiovascularDec 2026
NCT06218199ValsartanPhase 4Heart Failure, CongestiveCardiovascularDec 2026
NCT04055428ValsartanPhase 2Diabetes MellitusMetabolic and endocrineDec 2026
NCT06493526Mycophenolate MofetilPhase 4Kidney TransplantationGenitourinaryDec 2026
NCT04971720ValsartanPhase 2ObesityCardiovascularJan 2027
NCT05538208Mycophenolate MofetilPhase 2Lupus NephritisImmunologyJan 2027
NCT07215637CKD-512Phase 1Advanced Solid TumorsOncologyMar 2027
NCT03192397Mycophenolate MofetilPhase 1Acute Myeloid Leukemia in RemissionOncologyMay 2027
NCT05436418Mycophenolate MofetilPhase 1Peripheral Blood Stem Cell TransplantationOncologyJun 2027
NCT06053580ValsartanPhase 2Pulmonary Arterial HypertensionCardiovascularJul 2027
NCT06916793CKD-843Phase 3Androgenetic AlopeciaImmunologySep 2027
NCT05805605Mycophenolate MofetilPhase 2Acute Myelogenous LeukemiaOncologyOct 2027
NCT04477200Mycophenolate MofetilPhase 1Recurrent GlioblastomaOncologyNov 2027
NCT05465031ValsartanPhase 4Breast CancerOncologyDec 2027
NCT06655480ValsartanPhase 2HFpEFCardiovascularDec 2027
NCT07663422Mycophenolate MofetilPhase 2Immune-mediated HepatitisInfectious diseaseMar 2028
NCT06354179Mycophenolate MofetilPhase 4Liver TransplantationOtherApr 2028
NCT07572032ValsartanPhase 4Heart Failure Due to Coronary Artery DiseaseCardiovascularMay 2028
NCT00882895Mycophenolate MofetilPhase 2Lymphoma, Non-HodgkinOncologyJun 2028
NCT05508035ValsartanPhase 3Heart Failure With Moderately Reduced Ejection FractionCardiovascularAug 2028
NCT06704633ValsartanPhase 4Heart FailureCardiovascularNov 2028
NCT05194111ValsartanPhase 1Heart FailureCardiovascularNov 2028
NCT05207358Mycophenolate MofetilPhase 4Lupus NephritisImmunologyDec 2028
NCT05236036Mycophenolate MofetilPhase 1AstrocytomaOncologyJan 2029
NCT07539298ValsartanPhase 2Atrial Functional Mitral RegurgitationCardiovascularMay 2029
NCT07631156ValsartanPhase 4Heart Failure With Reduced Ejection FractionCardiovascularJun 2029
NCT06676384Mycophenolate MofetilPhase 4IgA NephropathyGenitourinaryAug 2029
NCT05155137ValsartanPhase 3StrokeNeurologyDec 2029
NCT07439094CKD-703Phase 1Advanced Solid TumorsOncologyDec 2029
NCT06568549Mycophenolate MofetilPhase 4Kidney TransplantationGenitourinaryDec 2030
NCT06568549Mycophenolate MofetilPhase 4Kidney TransplantationGenitourinaryDec 2030
NCT06799195Mycophenolate MofetilPhase 2Hematological MalignanciesOncologyApr 2031
NCT06930885ValsartanPhase 3Atherothrombotic DiseasesCardiovascularMay 2031
NCT05027945Mycophenolate MofetilPhase 2ImmunodeficiencyHematologyJul 2031

Targets

AGTR1 (1) IMPDH1 (1) IMPDH2 (1) IL23A (1) MET (1)

Companies with the same targets

Johnson & Johnson (Janssen) AstraZeneca Chia Tai Tianqing Pharmaceutical Group AbbVie Roche Eli Lilly Innovent Biopharmaceutical Technology (Hangzhou) Exelixis Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical THPharm

Companies built like this

Sun Pharmaceutical Industries Ganzhou Hemay Pharmaceutical Yuhan Beijing InnoCare Pharma Tech Sunshine Guojian Pharmaceutical (Shanghai)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.